Boston Scientific Corporation (NYSE:BSX) – Research analysts at SunTrust Banks boosted their Q2 2018 earnings per share estimates for Boston Scientific Corporation in a research report issued on Monday. SunTrust Banks analyst B. Nudell now anticipates that the medical equipment provider will earn $0.36 per share for the quarter, up from their prior estimate of $0.35. SunTrust Banks also issued estimates for Boston Scientific Corporation’s Q4 2018 earnings at $0.40 EPS.

Boston Scientific Corporation (NYSE:BSX) last announced its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same quarter in the previous year, the business earned $0.27 EPS. Boston Scientific Corporation’s revenue for the quarter was up 6.2% compared to the same quarter last year.

WARNING: “Q2 2018 EPS Estimates for Boston Scientific Corporation (NYSE:BSX) Lifted by SunTrust Banks” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/04/q2-2018-eps-estimates-for-boston-scientific-corporation-nysebsx-lifted-by-suntrust-banks.html.

A number of other equities research analysts also recently commented on BSX. Jefferies Group LLC raised their price objective on shares of Boston Scientific Corporation from $26.00 to $28.00 and gave the company a “hold” rating in a research report on Friday, April 7th. Guggenheim restated a “buy” rating on shares of Boston Scientific Corporation in a research report on Wednesday, April 12th. Zacks Investment Research upgraded shares of Boston Scientific Corporation from a “sell” rating to a “hold” rating in a research report on Monday, April 24th. TheStreet upgraded shares of Boston Scientific Corporation from a “c+” rating to a “b” rating in a research report on Tuesday, April 25th. Finally, Needham & Company LLC restated a “buy” rating and issued a $30.00 price objective (up previously from $29.00) on shares of Boston Scientific Corporation in a research report on Thursday, April 27th. One research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $30.06.

Shares of Boston Scientific Corporation (NYSE:BSX) traded up 0.34% during trading on Wednesday, hitting $26.83. The company had a trading volume of 3,568,109 shares. The firm has a market capitalization of $36.77 billion, a P/E ratio of 48.00 and a beta of 1.09. Boston Scientific Corporation has a 52-week low of $19.67 and a 52-week high of $28.51. The stock’s 50-day moving average is $27.64 and its 200 day moving average is $25.93.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Quadrant Capital Group LLC boosted its stake in Boston Scientific Corporation by 10.3% in the first quarter. Quadrant Capital Group LLC now owns 5,201 shares of the medical equipment provider’s stock valued at $122,000 after buying an additional 487 shares during the last quarter. Bronfman E.L. Rothschild L.P. boosted its stake in Boston Scientific Corporation by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock valued at $125,000 after buying an additional 338 shares during the last quarter. Guardian Life Insurance Co. of America boosted its stake in Boston Scientific Corporation by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock valued at $131,000 after buying an additional 49 shares during the last quarter. Commerce Bank purchased a new stake in Boston Scientific Corporation during the first quarter valued at approximately $207,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Boston Scientific Corporation during the first quarter valued at approximately $215,000. 91.96% of the stock is owned by institutional investors and hedge funds.

In other news, EVP Kevin J. Ballinger sold 28,864 shares of the firm’s stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $26.14, for a total transaction of $754,504.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Daniel J. Brennan sold 92,158 shares of the firm’s stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $27.48, for a total transaction of $2,532,501.84. Following the transaction, the chief financial officer now directly owns 235,421 shares of the company’s stock, valued at $6,469,369.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 216,156 shares of company stock valued at $5,899,982. Corporate insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Earnings History and Estimates for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.